Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Rhea-AI Summary

Alterity Therapeutics (NASDAQ: ATHE) has appointed Abby Macnish Niven as Company Secretary, following her recent appointment as Chief Financial Officer on September 30, 2024. She succeeds Phillip Hains in the secretary role effective November 18, 2024. Macnish Niven brings extensive experience in private wealth management from ANZ, UBS, and Ord Minett, and consults on governance, finance, and corporate structure. She holds Bachelor degrees in Commerce and Science from the University of Western Australia and is a Chartered Finance Analyst. In this role, she will be responsible for communications between Alterity and ASX.

Positive

• Appointment of dual role CFO/Company Secretary streamlines corporate leadership
• New officer brings extensive financial and wealth management experience from major institutions
• Strong educational background and professional credentials (CFA)

Negative

• None.

MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), has announced the appointment of Abby Macnish Niven as Alterity’s Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024.

The Board and Management of Alterity thank Phillip for his valuable contributions over the past several years and appreciate the foundation he helped establish.

Ms Macnish Niven was appointed as CFO on 30 September 2024 and has extensive experience in private wealth management with groups including ANZ, UBS and Ord Minett. Ms Macnish Niven consults to a range of listed and unlisted companies in governance, finance and corporate structure. Ms Macnish Niven holds Bachelor of Commerce and Bachelor of Science degrees from the University of Western Australia and is a Chartered Finance Analyst.

For the purposes of ASX Listing Rule 12.6, Ms Macnish Niven will be the person responsible for communications between the Company and ASX.

About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.

Authorisation & Additional information
This announcement was authorised by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:

Australia
Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255

U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386

Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

FAQ

When did Abby Macnish Niven become Company Secretary of Alterity Therapeutics (ATHE)?

Abby Macnish Niven became Company Secretary of Alterity Therapeutics on November 18, 2024.

What positions does Abby Macnish Niven hold at Alterity Therapeutics (ATHE)?

Abby Macnish Niven holds both the Chief Financial Officer position (since September 30, 2024) and Company Secretary position (since November 18, 2024) at Alterity Therapeutics.

What is Abby Macnish Niven's professional background before joining Alterity Therapeutics (ATHE)?

She has extensive experience in private wealth management with ANZ, UBS, and Ord Minett, and consults to listed and unlisted companies in governance, finance, and corporate structure.